Neurological protein may hold the key to novel depression treatments
November 30th, 2010 - 4:30 pm ICT by ANILondon, Nov 30 (ANI): Scientists have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile.
Neuroscientists at the Centre for Addiction and Mental Health (CAMH) found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression.
“We identified a potential therapeutic target for development of novel anti-depressants.” said Dr. Fang Liu, Principal Investigator and Senior
Scientist in CAMH’s Neuroscience Program and Associate Professor of Psychiatry at the University of Toronto.
Working from this discovery, researchers sought to find a way to disrupt coupling between the two receptors in hopes that it would have an anti-depressant effect.
Using an autopsied brain study, Dr. Liu and her team initially found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression.
They started by analyzing a specific dopamine signaling mechanism, the D1 and D2 receptor complex, to identify the sites where the two receptors bind together. With this information, they were able to generate a protein peptide to disrupt the binding of the two receptors. The peptide was then tested in animal models to compare the effects with existing anti-depressant medications.
“After we administered the peptide, we saw a marked improvement in depression-related behaviors. The improvement seen in the peptide group was equivalent to the improvement on traditional anti-depressant medication”.
This peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters.
These conventional antidepressant medications don’t work for all patients, and can cause various side effects. “We are hopeful that our research will lead to new options for treatment that might have reduced side effects for patients with depression,” Dr Liu stated.
The study has been published in this month’s Nature Medicine. (ANI)
- Depression cure with little side-effects found - Dec 01, 2010
- How anti-depressants create brain cell - Apr 13, 2011
- Diabetes linked to schizophrenia - Jun 09, 2010
- Delating a gene works up smarter brain - Mar 11, 2012
- New target for antidepressants revealed - Jun 01, 2010
- Illegal party drug may drive away the blues within 40 minutes - Sep 14, 2010
- The mere sight, smell of food hikes dopamine levels in binge eaters - Mar 01, 2011
- Engineered protein has potential for new anti- inflammatory treatment - Mar 11, 2011
- Parkinson's drug effective in treating restless leg syndrome - Dec 07, 2010
- Foods to Help You Sleep, Fight Depression - Aug 28, 2010
- Genetically defective mice to help understand human depression - Jun 30, 2010
- Anti-depressants doing more harm than good: Study - Apr 25, 2012
- 'Gene fix' to treat depression - Oct 22, 2010
- Gene therapy to brain may treat major depression - Oct 21, 2010
- Anti-depressants boost brain cells after injury - Apr 19, 2011
Tags: addiction and mental health, animal models, anti depressant medication, anti depressant medications, anti depressants, antidepressant medications, brain study, depressant effect, depression treatments, dopamine receptors, dr liu, fang liu, major depression, neuroscience program, novel type, peptide group, side effect profile, therapeutic target, treating depression, treatment for depression